These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

59 related articles for article (PubMed ID: 13483762)

  • 1. [Effects of vasolastine in dementia arteriosclerotica].
    BUIS C; HUTTER D
    Ned Tijdschr Geneeskd; 1957 Sep; 101(37):1690-4. PubMed ID: 13483762
    [No Abstract]   [Full Text] [Related]  

  • 2. [Effects of vasolastine on experimental sclerosis in rats and in dogs and patients with arteriosclerotic symptoms].
    HOOGERWERF S
    Geneeskd Gids; 1955 Mar; 33(5):85-93. PubMed ID: 14366210
    [No Abstract]   [Full Text] [Related]  

  • 3. Vasolastine in the treatment of arteriosclerosis.
    NOORDSIJ AJ; SMITH JA
    Am J Psychiatry; 1958 Mar; 114(9):836. PubMed ID: 13508908
    [No Abstract]   [Full Text] [Related]  

  • 4. [Treatment of atherosclerosis with vasolastine].
    NOORDSIJ AJ; SMITH JA
    Ned Tijdschr Geneeskd; 1958 Oct; 102(42):2040-4. PubMed ID: 13613399
    [No Abstract]   [Full Text] [Related]  

  • 5. [The effects of vasolastine on experimental sclerosis in rats and arteriosclerosis in humans].
    HOOGERWERF S
    Arztl Forsch; 1955 Nov; 9(11):I/540-6. PubMed ID: 13302006
    [No Abstract]   [Full Text] [Related]  

  • 6. Reserpine in the treatment of organic and senile psychosis.
    ABD-EL-NABY S
    J Egypt Med Assoc; 1957; 40(9):666-81. PubMed ID: 13525540
    [No Abstract]   [Full Text] [Related]  

  • 7. Psychiatric aspects of ageing.
    Mulligan JA
    Gerontol Clin (Basel); 1968; 10(3):139-45. PubMed ID: 5647001
    [No Abstract]   [Full Text] [Related]  

  • 8. Practice parameter: evaluation and treatment of depression, psychosis, and dementia in Parkinson disease (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology.
    Montgomery EB
    Neurology; 2007 Jan; 68(1):81; author reply 81. PubMed ID: 16585044
    [No Abstract]   [Full Text] [Related]  

  • 9. Practice parameter: evaluation and treatment of depression, psychosis, and dementia in Parkinson disease (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology.
    Aarsland D; Emre M; Lees A; Poewe W; Ballard C
    Neurology; 2007 Jan; 68(1):80; author reply 81. PubMed ID: 17200503
    [No Abstract]   [Full Text] [Related]  

  • 10. [Peyote alkaloids in the therapy of autonomic neurological conditions & especially in rheumatic heart disease & presenile states].
    WAHL M
    Gaz Med Fr; 1958 Sep; 65(17):1397-9. PubMed ID: 13586559
    [No Abstract]   [Full Text] [Related]  

  • 11. [5 years of vasolastine therapy].
    HOOGERWERF S
    Geneeskd Gids; 1960 Dec; 38():553-7. PubMed ID: 13715706
    [No Abstract]   [Full Text] [Related]  

  • 12. [Premature failure conditions].
    Bronisch FW
    Wien Med Wochenschr; 1968 Feb; 118(5):83-6. PubMed ID: 5664024
    [No Abstract]   [Full Text] [Related]  

  • 13. [Clinical observations on citrogenase-aminoxidase-tyrosinase (Vasolastine)].
    de Oliveira JM
    Hospital (Rio J); 1968 Sep; 74(3):751-4. PubMed ID: 5303759
    [No Abstract]   [Full Text] [Related]  

  • 14. Practice Parameter: evaluation and treatment of depression, psychosis, and dementia in Parkinson disease (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology.
    Miyasaki JM; Shannon K; Voon V; Ravina B; Kleiner-Fisman G; Anderson K; Shulman LM; Gronseth G; Weiner WJ;
    Neurology; 2006 Apr; 66(7):996-1002. PubMed ID: 16606910
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Protein, lipid & glycoprotein metabolism in senile dementia & arteriosclerotic dementia].
    ANTONINI FM; SALVINI L; PIAZZESI W
    Riv Patol Nerv Ment; 1957; 78(1):13-31. PubMed ID: 13466940
    [No Abstract]   [Full Text] [Related]  

  • 16. [Possible significance of dysmetabolic factors in senile dementia & arteriosclerotic dementia].
    PIAZZESI W
    Riv Patol Nerv Ment; 1957; 78(1):32-52. PubMed ID: 13466941
    [No Abstract]   [Full Text] [Related]  

  • 17. [Effect of enzyme therapy on sclerosing processes].
    GRUNDEL A
    Medizinische; 1958 Dec; 32(49):2011-4. PubMed ID: 13612661
    [No Abstract]   [Full Text] [Related]  

  • 18. [Enzyme therapy of arteriosclerotic diseases].
    HAMMERL H; KLEIN K; SIEDEK H
    Arztl Forsch; 1959 Jun; 13(6):300-4. PubMed ID: 13670056
    [No Abstract]   [Full Text] [Related]  

  • 19. [Trial therapy of atherosclerosis with enzyme preparations. I. Clinical part].
    KUCEROVA L; STORK A; FABIAN E
    Cas Lek Cesk; 1959 Mar; 98(13):403-7. PubMed ID: 13652143
    [No Abstract]   [Full Text] [Related]  

  • 20. [New therapeutic possibilities in cerebral arteriosclerosis].
    WILLINGE WITTERMANS A
    Belg Tijdschr Geneesk; 1956 May; 12(9):480-3. PubMed ID: 13328779
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 3.